Omnicell, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed February 28, 2024. Omnicell provides medication-management automation, software, consumables, and services to healthcare providers and pharmacies. It reports as one operating segment.
Financial performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $1,147.1 million | $1,295.9 million | Down 11% |
| Product revenue | $708.6 million | $903.2 million | Down 22% |
| Services and other revenue | $438.6 million | $392.7 million | Up 12% |
| Gross profit / margin | $496.8 million / 43% | $589.0 million / 45% | Margin down 2 points |
| Operating income (loss) | ($34.9 million) | ($2.3 million) | Loss widened |
| Net income (loss) | ($20.4 million) | $5.6 million | Shifted to loss |
| Diluted EPS | ($0.45) | $0.12 | Shifted to loss |
| Operating cash flow | $181.1 million | $77.8 million | Up $103.3 million |
Product revenue weakness primarily reflected lower automated dispensing-system volumes amid customer capital-budget and labor constraints. Services growth included Advanced Services revenue of $212.7 million, up from $186.0 million, and technical services revenue growth. Product mix and fixed production costs contributed to lower gross margin. Selling, general and administrative expense declined 11% and research and development expense declined 7%.
Cash and cash equivalents were $468.0 million at year-end, versus $330.4 million a year earlier; working capital was $559.8 million and the current ratio was 2.5. Cash from operations benefited from lower receivables and inventory and higher deferred revenue. Capital expenditures were $41.5 million, with a further $13.5 million spent on external-use software development.
Convertible senior notes had $575 million principal and a $569.7 million net carrying value; they bear 0.25% interest and mature in September 2025. No borrowings were outstanding under the $350 million revolving credit facility, and the company reported covenant compliance. The filing cites $576.4 million of note-related payments for 2025–2026 in its contractual-obligations schedule.
Material changes and operating developments
- Bookings fell 19%, from $1.054 billion to $854 million, primarily on lower-than-expected Advanced Services orders, especially Central Pharmacy Dispensing and IV Compounding services.
- Total backlog declined to $1.143 billion from $1.215 billion. Product backlog fell to $610.8 million from $797.0 million, while Advanced Services backlog rose to $531.9 million from $418.5 million.
- U.S. revenue represented 88% of total revenue, compared with 90% in 2022.
- Headcount declined by approximately 580 to about 3,650, reflecting restructuring actions announced in November 2022 and November 2023.
- There were no share repurchases in 2023; approximately $52.2 million of shares were repurchased in 2022.
Outlook, risks, and unusual items
The filing provides no specific numerical revenue or earnings guidance. Management expects cash, operating cash flows, and available revolver capacity to meet needs for at least the next 12 months and anticipates resources will support the business beyond that period. Its strategy emphasizes cloud migration, subscription and Advanced Services growth, and continued investment in automation and the “Autonomous Pharmacy” platform. Management also notes near-term customer delays and moderated Point of Care demand, including as the prior-generation replacement cycle largely runs its course.
- Restructuring: FY2023 employee-related restructuring expense was $15.5 million, net of reversals; $8.9 million remained unpaid at year-end. The company also recorded $10.0 million of facility right-of-use asset impairment and abandonment charges and $1.0 million of other long-lived asset impairment.
- Cybersecurity: The May 2022 ransomware incident delayed invoicing and implementations in 2022. The company says affected processes returned to normal and it does not expect a material adverse financial impact. Cumulative incident costs were $13.6 million, partially offset by $12.2 million in insurance recoveries, all received by year-end 2023.
- Contingencies: Omnicell is involved in various legal proceedings. It recorded no material legal accrual, stating that a material loss was reasonably possible but not probable and that any range of loss could not be reasonably estimated. The filing also describes uncertainty from litigation and manufacturer restrictions affecting the 340B program.
- Key risks: Customer budget and staffing constraints, lengthy sales and installation cycles, competition and pricing pressure, subscription renewal and service-delivery risks, debt and note-conversion liquidity or dilution exposure, cybersecurity and privacy regulation, and reliance on limited suppliers. A material portion of revenue is linked to members of the ten largest GPOs and federal agencies (64% in 2023), though no individual customer exceeded 10% of revenue.
- Financial reporting: Management and the auditor concluded internal control over financial reporting was effective; the financial-statement audit opinion was unqualified. The auditor identified inventory valuation and capitalization of internal-use software costs as critical audit matters.
Important facts for investors to verify
- Whether bookings and product backlog stabilize, and whether reported backlog converts to revenue on expected timelines.
- Whether Advanced Services growth, customer renewals, and service margins can offset weaker equipment demand.
- Whether restructuring savings improve operating profitability enough to restore margins.
- Cash generation relative to the $575 million note principal due in 2025, covenant requirements, and potential early-conversion conditions.
- Progress on cloud migration and software capitalization, including the assumptions used for inventory valuation and future demand.
- Developments in 340B regulation and litigation, open legal matters, supplier availability, and cybersecurity exposure.